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Summary We have cloned and characterized a 77-kDa oestrogen receptor (ER) from an oestrogen-independent subclone of the MCF-7
human breast cancer cell line. This receptor contains an in-frame, tandem duplication of exons 6 and 7, located in the steroid-binding domain
of the ER. This mutation has abrogated ligand binding, but not DNA binding, in this mutant ER. We previously described the partial structure
of a unique oestrogen receptor (ER) that is expressed in an oestrogen-independent MCF-7:2A subclone of the breast cancer cell line MCF-7
(Pink JJ, Wu SQ, Wolf DM, Bilimoria MM, Jordan VC 1996a, Nucleic Acids Res 24 962-969). Sequence analyses determined the molecular
weight ofthis 80-kDa ER to be 77 kDa, and hereafter this protein will be designated as ER77. Examination of the entire coding sequence of the
ER77 mRNA indicates that it contains a tandem duplication of exons 6 and 7. Using a coupled transcription/translation system, a 77-kDa ER,
which corresponds to the protein observed in the MCF-7:2A cells, was expressed. The ER77 protein does not bind the ligands [3H] oestradiol
or [3H]tamoxifen aziridine. In DNA binding gel shift assays, the in vitro synthesized ER77 binds to a consensus vitellogenin A2 oestrogen-
response element. In transient transfection experiments, the mutant ER, alone or in combination with the wild-type ER, does not induce
expression of an oestrogen-responsive luciferase reporter construct. In fact, expression of the ER77 in the ER-positive T47D:A18 cell line
inhibits E2-induced luciferase expression. Overexpression of wild-type ER in T47D:A18 cells leads to elevated constitutive expression of the
luciferase reporter, which was inhibited by co-transfection with ERR7. These data suggest that the ER77 can interfere with normal ER activity
and does not act as a constitutive activator of oestrogen-independent growth in MCF-7:2A cells. Consequently, the constitutive growth
observed in MCF-7:2A cells is probably the result of other ER-mediated pathways.
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The development of oestrogen-independent growth in previously
oestrogen-dependent breast cancer is the single most significant
problem in the clinical treatment of this disease (Paik et al, 1994;
Paridaens, 1995). The oestrogen receptor (ER)-positive, oestrogen-
responsive breast cancer cell line MCF-7 has been used as a model
overthe past 20 years (Brooks et al, 1973; Soule et al, 1973). More
recently, these cells have been used to study the development
of oestrogen-independent growth in breast cancer cells. The
discovery in 1986 ofthe oestrogenic activity present incommercial
preparations of the pH indicator, phenol red, and its subsequent
removal from tissue culture media, has allowed the growth of cell
lines in truly oestrogen-free media (Berthois et al, 1986). This
finding led our laboratory, as well as others, to investigate the
changes in the MCF-7 cell line that allowed these cells to adapt to
growth in oestrogen-free media. Short-term studies showed that
MCF-7 cells consistently expressed high levels of the ER
following oestrogen removal, even as the growth of these cells
became oestrogen independent. Interestingly, this basal growth in
oestrogen-free media could be inhibited by a number of different
Received 7May 1996
Revised 10July 1996
Accepted 12July 1996
Correspondence to: VC Jordan, Robert H Lurie Cancer Center, Northwestern
University Medical School, 303 East Chicago Avenue, Olsen Pavilion
8258, Chicago, IL 60611, USA. Present address: National Cancer
Institute, Laboratory of Pathology, Building 10, Room 2N206, Bethesda,
MD 20892, USA
anti-oestrogens (Katzenellenbogen et al, 1987; Welshons and
Jordan, 1987). This phenotype was believed to be an intermediate
step in the development oftrue anti-oestrogen resistance.
In order to study the development of oestrogen-independent
growth, we characterized a number ofclones derived from MCF-7
cells, which were cultured in oestrogen-free mediafor more than 2
years. Each of these clones exhibited unique characteristics;
however, they all continue to express high levels ofactive ER. One
previously described clone, MCF-7:5C, became anti-oestrogen
resistant, while continuing to express a functional wild-type ER
(Jiang et al 1992a). Another oestrogen-independent clone, MCF-
7:2A, isolated from the same parental MCF-7 cell line, continues
to express wild-type ER. However, the growth of these cells is
inhibited by anti-oestrogens of both the pure and partial agonist
class (Pink et al, 1995).
In the present study, we describe MCF-7:2A cells, which
express wild-type ER, in addition to a unique 77 (kDa) mutant ER
(ER77), which contains a tandem, in-frame duplication of exons 6
and 7 (Pink et al, 1996a). The expression ofthe 77-kDa ER in ten
individual subclones of the MCF-7:2A cell line and its mainte-
nance for over 100 passages suggests that it is critical to the
oestrogen-independent growth ofthese cells (Pink et al, 1995). We
now report the cloning and complete sequencing ofthe 77-kDa ER
and a preliminary evaluation of the biology of the translated
protein receptor. Functional characterization ofthis unique protein
may offerinsights into the mechanismresponsible for the develop-
ment of oestrogen-independent growth in breast cancer. These
data may also shed light on at least one pathway that can lead to
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the development of oestrogen-independent and, possibly, anti-
oestrogen-resistant growth in breast cancer.
MATERIALS AND METHODS
Cell culture
MCF-7 cells were obtained from Dean Edwards (at the San
Antonio Breast Cancer Group, TX, USA) (originally obtained
from the Michigan Cancer Foundation, Detroit, MI, USA). T47D
(Keydar et al, 1979) and MDA-MB-231 (Caileau et al, 1974) cells
were obtained from the American Type Culture Collection,
Rockville, MD, USA All tissue culture components were obtained
from Gibco Laboratories, Grand Island, NY, USA, unless other-
wise stated. MCF-7:WS8, T47D:A18 and T47D:C4:2W cells
were grown in RPMI-1640 containing 10% heat-inactivated
fetal bovine serum (FBS; Bioproducts for Science, Indianapolis,
IN, USA), 6 ng ml-1 bovine insulin, 2 mM L-glutamine, 100 U ml-'
penicillin, 100,g ml-' streptomycin and 250 ng ml-1 amphotericin
B (fully oestrogenized medium). MCF-7:2A and MDA-MB-231:
1OA cells were routinely grown in oestrogen-free medium, which
substitutes phenol red-free RPMI and 3x dextran-coated charcoal-
treated FBS. Cells were passed at 1:10-1:20 dilutions once per
week using 0.1% trypsin.
MCF-7:WS8 is a clone of the MCF-7 cell line grown in
oestrogen-containing medium. This cell line is dependent on
oestrogen for maximum growth and ER-mediated gene expression
(Pink et al, 1995). The clone MCF-7:2A was isolated from the
same parental MCF-7 cell line following growth in oestrogen-free
medium for more than 8 months (Jiang et al, 1992a). MCF-7:2A
cells now grow maximally in oestrogen-free media; however,
MCF-7:2A cells are inhibited by anti-oestrogens. The MCF-7:2A
clone also expresses a mutant ER, which migrates at approxi-
mately 77 kDa. This mutant ER has been observed in ten indi-
vidual subclones ofthis cell line and has been expressed for more
than 100 passages (Pink et al, 1995). T47D:A18 is an ER- and
progesterone receptor (PR)-positive, oestrogen-dependent clone
derived from the T47D cell line. T47D: C4:2W is an ER- and
PR-negative clone derived from T47D, following growth in
oestrogen-free media for more than 1 year (Murphy et al, 1989,
1990; Pink et al, 1996b).
Western blotting
Whole cell extracts were prepared by direct lysis of phosphate-
buffered saline (PBS)-washed cells in 1 x sample buffer (10%
glycerol, 150 mM Tris-HCI, pH 6.8, 0.5 mm EDTA, 0.125%
sodium dodecyl sulphate (SDS), 1% P-mercaptoethanol and 5 jig
ml-' bromphenol blue) followed by immersion in a boiling water
bath for 5-10 min. Equal amounts of protein were run in a stan-
dard Western blot as described previously (Pink et al, 1995) with
the following changes. The secondary antibody used was a horse-
radish peroxidase (HRP)-conjugated goat anti-rat antibody
(HyClone Laboratories, Logan, UT, USA), and visualization was
accomplished using the ECL visualization kit (Amersham
Arlington Heights, IL, USA) according to the manufacturer's
directions. The membrane was wrapped in plastic film and
exposed to Kodak X-Omat film for 15s and developed.
XL-PCR-mediated cloning of the wild-type ER and ERn
Poly-A+-enriched RNA was prepared from MCF-7:WS8 and
MCF-7:2A cells grown in oestrogen-free medium by direct
isolation (Badley et al, 1988). Poly A+-enriched RNA, 5 jg
per reaction, was reverse transcribed using Moloney murine
leukaemia virus (MMLV) reverse transcriptase primed with
oligo (dT)12 18 (Gibco BRL, Gaithersburg, MD, USA). XL-PCR
(Perkin-Elmer, Foster City, CA,USA) was then performed using
10% of this reaction and 100 ng of an upstream primer, which
binds 10 bases 5' of the translation start signal (Ul, GCCACG-
GACCATGACCATGA), and a downstream primer, which
binds 3' of the translation termination signal (D5,
TGTGGGAGCCAGGGAGCTCT) (Oligos Etc., Wilsonville, OR,
USA) as per the manufacturer's directions. Polymerase chain reac-
tion (PCR) was run for a total of 31 cycles in a DNA thermal
cycler (Perkin-Elmer-Cetus, Foster City, CA, USA), 1 min at
93°C, 12 min at 68°C for 16 cycles followed by 15 additional
cycles as above, with a 15s per 68°C cycle extension and a final
20 min extension at 72°C. The PCR products were then blunt
end ligated into the SmaI site of pUC18 using the Sure Clone
Ligation kit (Pharmacia Biotech, Piscataway, NJ, USA). These
clones were then digested with BamHI to expose the 5' end ofthe
insert. The ends were filled using Klenow polymerase, and EcoRI
linkers were ligated to the blunt ends. The full-length cDNA was
liberated by digestion with EcoRI, gel purified and subcloned
into the EcoRI site ofpSG5 (Green et al, 1988). A sense and anti-
sense clone of each ER cDNA was then selected for further char-
acterization. The sequence of the entire cDNA inserts of both the
wild-type ER and ER77 were then determined using standard
dideoxy chain termination methodology. The sequencing reaction
was performed using Sequenase T7 DNA Polymerase (version
2.0, United States Biochemical, Cleveland, OH, USA) as per the
manufacturer's instructions.
Coupled in vitro transcription/translation of ER
The TNT Coupled Reticulocyte Lysate transcription/translation
system (Promega Madison, WI, USA) was used to drive the
synthesis ofthe ER proteins from the T7 promoter in pSG5 as per
the manufacturer's directions. Radiolabelled protein was synthe-
sized by including [35S]methionine (Amersham) in the reaction
mixture. These extracts were denatured by boiling in 1 x sample
buffer and run on a 10% polyacrylamide SDS gel with a 4%
stacking gel, fixed in 50% methanol-10% acetic acid and dried.
The dried gel was exposed to radiographic film for 1 h and devel-
oped. The ER proteins were also synthesized in a reaction using
only radioinert amino acids and run in a Western blot using the
methods described above.
Hydroxylapaptite binding assay
Oestradiol-binding assays were performed as described previously
(Fritsch et al, 1993). Briefly, variable amounts of in vitro synthe-
sized ERs were mixed with [3H]17p-oestradiol (E2) (40 nM
final E2 concentration) for 1 h at 4°C in 200gl total volume.
Hydroxylapatite (HAP) [0.25 ml of a 70% (v/v) slurry] was then
added to this mixture along with 1 ml of 10 mm Tris, pH 7.5, and
incubated at 4°C for 30 min, with three mixings. The HAP was
pelleted and then washed four times with 2 ml of 10 mM Tris, pH
7.5. The bound [3H]oestradiol was then eluted in 0.75 ml of 100%
ethanol and counted in a Beckman LS 60001C scintillation
counter. To determine non-specific binding, the reaction was done
in parallel with the addition of8gM diethylstilboestrol (DES), and
specific binding was determined by subtracting non-specific
counts from total counts.
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[3H]tamoxifen aziridine binding
This reaction was performed as described previously (Fritsch et al,
1992). Briefly, cells were grown in oestrogen-free media for
4 days and cytosols were prepared. The cytosols were then incu-
bated with 120 nm [3H]tamoxifen aziridine in a reaction either
without (H) orwith (HC) 6 gM radioinertDES for90min at4°C. An
equal volume of 2 x sample buffer was then added and the samples
were boiled for 5 min. Amounts of cytosols containing equal
[3H]oestradiol binding, as measured in aHAP assay, were then sepa-
rated by SDS-PAGE. The gel was fixed with 10% acetic acid and
50% methanol and then incubated with the fluor Enhance for 1 h at
room temperature. Finally, the gel was washed with distilled water,
dried and exposed to radiographic film at-70°C for 14 days.
Gel shift assays
Gel shift assays were performed using the components provided in
the BandShift kit (Pharmacia Biotech). All binding reactions
contained 10 mM Tris-HCl (pH 7.5), 50 mm sodium chloride 3 mM
dithiothreitol (DTT), 10% glycerol, 0.05% NP-40, 0.1 mm zinc
chloride, 50 jig ml-' poly (dI-dC) and 1 ng of labelled oligonu-
cleotide. Oligonucleotides were labelled with Klenow polymerase.
Binding reactions were carried out overnight at 4°C or at room
temperature for 1 h. For supershift experiments, 1 jg ofthe mono-
clonal antibody H222 (Greene et al, 1980) was added during the
final 20 min of binding. Non-denaturing polyacrylamide gel elec-
trophoresis (4%) was carried out in the cold using 1 x low ionic
strength buffer (7 mm Tris HCl, pH 7.5, at 22°C, 3 mM sodium
acetate and 1 mM EDTA) with constant buffer recirculation.
Following electrophoresis, the gels were dried and exposed to
radiographic film.
Transient transfection assays
Cells were seeded into six-well plates (500 000 cells per well)
in phenol red-free RPMI plus 10% 3 x charcoal-stripped FBS.
The following day, medium was removed and replaced with
fresh oestrogen-free medium. A solution containing 1 jig of the
luciferase reporter construct, pVIT3-luc (Catherino and Jordan,
1995) and 0.5 jig ofthe ,-galactosidase reporter, pCMV3, plus the
appropriate amounts of the ER expression constructs (MacGregor
and Caskey, 1989) in 0.25 M calcium chloride was mixed dropwise
with an equal volume of2 x HBS (0.28 M sodium chloride, 0.05 M
Hepes, 1.5 mm sodium phosphate, pH 7.05) by gently bubbling air
through the solutions. Total DNA per group was equalized by
including the pSG5 vector alone as carrier. This solution was then
incubated at room temperature for 20 min to allow a DNA/calcium
phosphate precipitate to form. This solution was slowly added to
the cells and incubated at 37°C in a humidified incubator with 5%
carbon dioxide for 6 h. At that time, the DNA solution was
removed and medium, with or without compounds, was added to
the wells and incubated at 37°C in a humidified 5% carbon dioxide
incubator for an additional 18-48 h. The medium was removed
and the cells were washed once with ice-cold PBS. The cells were
then scraped in extraction buffer (0.1 M potassium hydrogen phos-
phate, pH 7.5, 1% Triton X-100, 100 jig ml-' bovine serum
albumin (BSA), 2.5 mM phenylmethylsulphonyl fluoride (PMSF)
and 1 mm DTT) and pipetted vigorously to ensure complete cell
lysis. Cell debris was pelleted by spinning in a microfuge for 1 min
and the lysate was stored on ice until luciferase activity was
assayed. Luciferase activity was assayed by mixing 50 gl of each
lysate with 350pl ofreaction buffer (160 mm magnesium chloride,
75 mm glycylglycine, pH 7.8, 0.5 mg ml-' BSA, 19 mg ml-' ATP
and 15 mm Tris-HCl, pH 7.5). To begin each assay, 100gl of
substrate (0.4 mg ml-' luciferin, potassium salt in 10 mm sodium
bicarbonate, pH 6.0) was automatically injected into the lysate
mixture. Each point was monitored for 10 s by a Monolight 2010B
luminometer (Analytical Luminescence Laboratory, San Diego,
CA, USA) andrelative luciferase units (RLUs) were then reported.
All points were corrected for transfection efficiency by dividing
RLU by 3-galactosidase activity.
3-Galactosidase activity was measured using a ,-methylumbel-
liferone (MUG) assay (Luyten et al, 1985). Briefly, an aliquot of
the cell extract was mixed with 1.3 ml of reaction buffer
containing 0.1 M sodium phosphate, 10 mm potassium chloride, 1
mm magnesium sulphate, pH 7.0, and 2.2 (10-5) g ml-' MUG
(Molecular Probes, Eugene, OR, USA). The sample was incubated
at room temperature for 1 h and 750 gl of stop buffer (15 mm
EDTA, 0.3 M glycine, pH 11.2) was added. The samples were then
read in an LS-5 fluorescence spectrophotometer (Perkin Elmer,
FosterCity, CA, USA) with excitation at 350 nm and absorption at
450 nm. All samples were correlated to a standard curve using
purified 3-galactosidase (Boehringer Mannheim Biochemicals,
Indianapolis, IN, USA)
RESULTS
Cloning of the wild-type ER and ER77full-length cDNAs
Previously, we showed that the mutant ER isolated from the MCF-
7:2A cells contains an in-frame duplication ofexons 6 and 7. This
was determined by partial PCR-mediated subcloning of a segment
ofthe ER cDNA, which comprised approximately one-half of the
coding sequence of the mutant ER (Pink et al, 1995). Calculation
of the molecular weight of this protein based upon the amino
sequence resulted in an estimate of77 kDa. This is in good agree-
ment with our initial estimate of 80 kDa, which was based solely
on migration in SDS-PAGE. We have designatedthis mutant ER as
ER77 for all future reference. A reverse transcriptase-polymerase
chain reaction (RT-PCR)-mediated approach was subsequently
used to clone the full-length cDNA for the mutant ER77, as well as
the wild-type 66-kDa ER present in the MCF-7:2A cell line. PCR
amplification ofa cDNA library from MCF-7:2A cells gave rise to
two major amplified products of approximately 1800 bp and
approximately 2100 bp. These blunt-ended products were cloned
into the SmaI site ofpUC18. Clones were then screened by PCR to
isolate plasmids containing the correct inserts. Clones containing
the wild-type ER (1800 bp) and ER77 (2100 bp) inserts were then
prepared and sequenced using standard dideoxynucleotide
methodology, as described in Materials and methods. These inserts
were subclonedinto theeukaryotic expression vectorpSG5 (Green
et al, 1988) for further examination. The coding sequence ofER77
is shown in Figure 1, with the duplicated exons highlighted.
Sequence analysis of the wild-type ER (sense orientation
pSG5:58-1; antisense orientation pSG5:58-3) showed no muta-
tions in the coding sequence when compared with the normal ER
(HEGO) sequence, as described by Tora et al (1989). The ER77
cDNA clones (sense orientation pSG5:91A; antisense orientation
pSG5:91C) were also sequenced and shown to contain a duplica-
tion ofexons 6 and 7 as described previously. No other alterations
were observed in the entire cDNA coding sequence.
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Figure 1 Coding sequence of the mutant ER77. Numbers refer to the amino acids sequence. Exon boundaries are as previously reported (Ponglikitmongkol
et al, 1988). The shaded region corresponds to the duplicated exons 6 and 7
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Figure 2 Translation of ER cDNAs in a reticulocyte lysate system. Equal
volumes of TNT coupled lysates programmed with pSG5-derived expression
vectors were denatured, run on an SDS polyacrylamide gel and probed in a
Western blot using the anti-ER antibody, H222. HEGO is the wild-type ER
cDNA originally described by Tora et al (1989). The wild-type ER and ER77
are ER cDNA clones isolated from MCF-7:2A cells, and these inserts in the
antisense orientation are also shown
Coupled in vitro transcription/translation of the
ER cDNAs
The pSG5 vector contains a T7 promoter upstream of the multiple
cloning site into which the ER cDNAs were cloned (Green et al,
1988). We tested the ability ofwild-type ER and ER77 constructs to
code forprotein thatcouldbeused to assessthe biochemical proper-
ties of these ERs. A reaction that allowed for the incorporation of
[35S]methionine was performed, and a quantity ofthat reaction was
then run on a standard SDS-polyacrylamide gel. HEGO and wild-
type ER translation gave rise to a single major band of approxi-
mately 66 kDa. The wild-type ER and ER77 antisense clones did not
yield any 35S-labelled proteins, as expected (data not shown).
Translation of the ER77 clone demonstrated a major 35S-labelled
protein at 77 kDa. This reaction was repeated with radioinert
methionine, andthe proteins wereprobedin aWestern blotusing the
monoclonal anti-ER antibody, H222. As observed in Figure 2, the
majorprotein species visualized by SDS-PAGE were recognized by
this specific antibody. The minor bands seen in the Western blot are
probably the result ofeither proteolytic cleavage, an internal codon
that causes premature termination of translation or, alternatively, a
cryptic initiation site upstream of the canonical start site that gives
rise to truncated proteins that still contain the epitope recognized by
the H222 antibody. These minor bands constitute less than 2% of
total ER synthesis and should not significantly affect the functional
studies described below. These data confirm that the clone,
pSG5:58-1, codes for a wild-type ER, and pSG5:91A codes for the
ER77, as first observed in the MCF-7:2A cells.
Ligand binding of the ER7
Following reticulocyte synthesis, wild-type and mutant ERs were
incubated in reactions containing 40 nM[3H]E2 at 4°C for 1 h.
Specific binding of [3H]E2 was then measured by HAP binding.
Non-specific binding was measured in parallel groups containing a
A
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Figure 3 Ligand binding of the wild-type and mutant ERs. (A) E2 binding of
in vitro synthesized ERs was measured in a HAP binding assay. See
Materials and methods for details. The average binding of four volumes of
lysate is shown. Groups are as described in Figure 2. (B) Binding of ER
isolated form MCF-7:WS8 and MCF-7:2A cells to [3H]tamoxifen aziridine.
Cytosols containing equal amounts of ER were mixed with [3H]tamoxifen
aziridine for 90 min at 40C alone (H) or in the presence of a 200-fold molar
excess of DES (HC). The samples were then denatured and run in a
standard SDS polyacrylamide gel, dried and exposed to radiographic film
200-fold molar excess of unlabelled DES. The results of this
experiment are shown in Figure 3A. For each group 1, 5, 10 and
25 ,ul of extract was incubated with the [3H]E2. Total specific
binding in each reaction was measured and specific binding per ,l
extract was calculated from each reaction. Both HEGO and the
wild-type ER isolated from MCF-7:2A cells bind [3H]E2. Neither
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Figure 4 Specific DNA binding of ERs isolated from the MCF-7:WS8 and
MCF-7:2A cell lines. Nuclear extracts were isolated from oestrogen-deprived
MCF-7:WS8 and MCF-7:2A cells. The indicated amount of each extract was
then mixed with a 32P-labelled 20-bp oligonucleotide containing the
vitellogenin A2 ERE for 30 min at 200C. The anti-ER antibody, H222, was
then added to the appropriate groups, and all reactions were incubated
for an additional 30 min at 200C. The reactions were then run on a 4.5%
-non-denaturing polyacrylamide gel and visualized by exposure to
radiographic film
ofthe antisense programmed extracts demonstrated any specific E2
binding. The ER77-containing extract failed to demonstrate any
specific ligand binding in this assay.
The ability of the 66-kDa and 77-kDa ER to bind ligand was
also measured in cytosols from MCF-7:2A and MCF-7:WS8 cells
by means of covalent binding to [3H]tamoxifen aziridine (Wei et
al, 1985). Cytosols from both MCF-7:WS8 and MCF-7:2A cells,
grown for 4 days in oestrogen-free medium, were incubated with
[3H]tamoxifen aziridine in the presence (HC) and absence (H) of a
200-fold molar excess of DES. As seen in Figure 3B, both cell
lines show specific binding of a 66-kDa species that was competed
by DES. However, MCF-7:2A cells did not show binding to any
species that corresponded to ER77. Together, these data demon-
strate that the exon duplication in the ligand-binding domain ofthe
ER77 protein has abrogated ligand-binding ability.
ERE* --
Figure 5 Specific DNA binding of ERs synthesized in vitro. Reticulocyte
lysate-synthesized ERs were mixed with a 32P-labelled 60-bp oligonucleotide
containing three copies of the vitellogenin A2 ERE. Following incubation at
40C overnight, H222 antibody was added to the appropriate groups and
incubated for 30 min at 200C. These reactions were then analysed as
described for Figure 4. The addition of 1 ,ug of H222 is noted by a (+). The
addition of a 100 x molar excess of cold ERE is noted in the last two lanes
DNA binding of the ER77
Gel shift analyses ofnuclear extracts from the MCF-7:2A cells did
not demonstrate any obvious higher molecular weight species that
could be the result of specific binding of the ER77 to a 20-bp
oligonucleotide, which contained a consensus vitellogenin A2
oestrogen-response element (ERE) (Figure 4). The MCF-7:2A
cytosol demonstrated higher binding per p1 of extract as would be
expected from its approximately two fold higher wild-type ER
expression. In order to measure the DNA binding of the ER77 in
the absence of the wild-type ER, we repeated this assay using the
in vitro synthesized ER77. For this assay, we used a 60-bp oligonu-
cleotide that contained three copies of the vitellogenin A2 ERE
separated by HindIII sites. Use of this oligo gave rise to much
stronger gel-shifted bands of similar mobility to those observed
with the 20-bp oligo containing a single ERE (data not shown).
Total I'S protein labelling showed that the reticulocyte extracts
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Figure 6 Transcriptional activity of transiently transfected ERs. pVIT3-Luc reporter (1 gg) was transfected into T47D:A18 (A and B) or T47D:C4:2W (C and D)
cells using a standard calcium phosphate technique, along with 0.5 ,g of the pCMV,B P-galactosidase plasmid, which served as a transfection control. Included
in these reactions was the noted quantity of the vectors coding for the wild-type ER or ER77. Six hours after the transection, fresh oestrogen-free medium
(A and C) or medium containing 1 nM E2 (B and D) was added. The cells were analysed for luciferase activity and J-galactosidase 42 later. All results were
corrected for ,B-galactosidase activity and presented as fold induction relative to cells with no exogenous ER expression vectors
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expressed approximately 25% less ER77 than HEGO protein perRl
ofextract. Western analyses demonstrated approximately 50% less
ER77 than wild-type ER when measured by H222 binding (see
Figure 2). DNA binding ofthe in vitro synthesized ERs are shown
in Figure 5. The wild-type ER demonstrated specific ERE binding,
which was supershifted by the ER-specific antibody, H222. The
ER7' extract gave rise to a shifted complex, which ran as a smear
from a site similar to that of the wild-type ER complex to a site
considerably higher in the gel. The H222 antibody specifically
bound to the ER77 complex and gave rise to a supershifted complex
that was clearly larger than that observed with wild-type ER. The
specificity of the DNA binding was shown by the ability of an
excess of cold ERE to inhibit the binding to the radiolabelled ERE
completely. In mixing experiments designed to assess the interac-
tion of the wild-type ER and ER77, no evidence of interaction or
heterodimerization of the two receptors has been observed (data
not shown).
Transient transfection studies
We next performed transient transfection studies in order to deter-
mine the ability of wild-type ER and ER77 to induce transcription
from an oestrogen-responsive promoter. For these studies, we used
a luciferase reporter construct, pVIT3-Luc, which contained the
same 60-bp oligonucleotide insert used in the DNA-binding
studies upstream of a minimal herpes simplex thymidine kinase
promoter. In previous studies, we demonstrated that this construct
was exquisitely sensitive to ER-mediated transcription (Catherino
and Jordan, 1995). The pSG5 (Green et al, 1988)-derived ER
expression vectors contain the SV40 early promoter, a rabbit ,-
globin intron II and an SV40 poly-A signal, which afforded consti-
tutive expression ofthese proteins. The cell lines that we chose for
these transfection studies are an ER-positive (T47D:A18) and an
ER-negative (T47D:C4:2W) clone ofthe human breast cancer cell
line, T47D. Comparable ER-positive and -negative clones are not
available for the MCF-7 cell line. The T47D:A18 clone exhibits a
dramatic growth response to oestrogens, which can be inhibited by
antio-estrogens. The T47D:C4:2W clone was derived from the
T47D cell line by long-term (>2 years) growth in oestrogen-free
media, and two rounds of limiting dilution cloning. This clone is
ER negative and completely devoid ofany measurable response to
either oestrogens or anti-oestrogens (Pink et al, 1996b).
In the absence of exogenous ER, T47D:A18 cells display an
approximately 100-fold induction ofluciferase activity in response
to oestradiol, as seen in lane 5 of Figure 6B. Addition of the wild-
type ER expression vector caused an approximately 50% increase
in this activity. However, co-transfection of ER77 with the wild-
type ER clearly caused a decrease in luciferase activity.
Additionally, transfection with the ER77 alone causes an even
greater inhibition of the endogenous oestradiol-in¶uced luciferase
activity in T47D:A18 cells (see lanes 7 and 8 of Figure 6B). In a
parallel experiment designed to assess the oestrogen-independent
function of the ER in T47D:AI8 cells, transfection of wild-type
ER caused an approximately 15-fold induction of luciferase
compared with T47D:A18 cells alone, (see lane 2 of Figure 6B).
This oestrogen-independent activity was not observed in the ER77-
transfected group. In fact, as seen in lane 3 of Figure 6B, the ER77
inhibits the oestrogen-independent activity of the wild-type ER.
T47D:C4:2W cells do not show significant oestrogen-indepen-
dent luciferase activity in any group, as shown in Figure 6C.
However, transfection of wild-type ER in these cells resulted in an
approximately 15-fold induction of luciferase activity in the pres-
ence of E2. In contrast to the T47D:A18 cells, ER77 in oestrogen-
free medium had no activity in the T47D:C4:2W cells (see Figure
6). However, ER77 inhibited the oestradiol-induced wild-type ER
activity when these two genes were co-transfected (compare lanes
6 and 7 in Figure 6D).
DISCUSSION
We used the MCF-7 cell line as a model system in order to
examine the adaptation of oestrogen-dependent breast cancer cells
to growth in oestrogen-free media. This cell line maintained
oestrogen-responsive growth when continuously cultured in
oestrogen-containing media. However, when cultured in
oestrogen-free media, MCF-7 cells underwent a slowing ofgrowth
and a subsequent crisis period, during which many of the cells
died (Katzenellenbogen et al, 1987; Welshons and Jordan, 1987).
Following this crisis, clones appeared that grew well in oestrogen-
free media. These adapted cells all appear to share two characteris-
tics. First, they continue to express the ER. Second, their
oestrogen-independent growth can be inhibited by anti-oestrogens.
From these oestrogen-independent MCF-7 cells, we isolated the
MCF-7:2A clone following two rounds of limiting dilution
cloning. While maintaining ER expression and sensitivity to the
growth-inhibitory effects of anti-oestrogens, MCF-7:2A cells
express a novel 77-kDa ER, in addition to the wild-type 66-kDa
ER (Pink et al, 1995, 1996a). Prior investigation of the function of
the mutant ER77 in MCF-7:2A cells was problematic owing to the
masking of the ER77 function by the wild-type ER. In MCF-7:2A
cells, the wild-type ER is expressed at three to ten fold greater
levels than that of the mutant receptor. In order to circumvent this
problem and to study the independent function of this mutant ER,
we cloned the full-length cDNA, which coded for the ER77.
Previously, we had cloned and sequenced a PCR-generated frag-
ment ofER77, which contained a duplication ofexons 6 and 7 (Pink
et al, 1996a). However, this fragment could not be used to prepare
a full-length cDNA for functional studies of the ER77, and there
was no evidence from our previous studies that point mutations
were not present elsewhere in the molecule. In the present study,
we demonstrate that the only alteration in the coding sequence of
the ER77 cDNA was the tandem duplication of exons 6 and 7. We
also used XL-PCR to clone the cDNA for the wild-type ER from
the MCF-7:2A cells to determine whether this receptor contained
any mutations in its coding sequence. Previously, our only
evidence that the wild-type ER from the MCF-7:2A cells was
normal was based on its apparent size (Pink et al, 1995, 1996a).
Here, we showed that the 66-kDa ER does not contain any muta-
tions in its coding sequence. This suggests that the abnormal ER
pathway present in the MCF-7:2A cells is not the result of previ-
ously undetected mutations in the 66-kDa ER. The presence of
the mutant ER77 in all ten subclones studied so far suggests that
this protein is associated with the development of the oestrogen-
independent phenotype observed in the MCF-7:2A cells. However,
this does not indicate that the presence of the ER77 is the only
defect in the ER-mediated signalling pathway; other alterations
may subsequently prove to be critical factors in the development of
oestrogen-independent growth in these unique cells.
Mutant and wild-type cDNA clones were further characterized by
synthesizing the ERs in an in vitro coupled reticulocyte transcrip-
tion/translation system. As we showed in Figure 2, the pSG5:58-1
clone expressed a 66-kDa ER, which is indistinguishable from the
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ER coded by the HEGO clone isolated by Green et al (1988). The
pSG5:91A clone, which contains the cDNA expressing ER77
demonstrated production of a single protein of expected size that
was recognized by two monoclonal antibodies to the ER (Figure 2
and data not shown). Addition ofthe antisense cDNAs in the reticu-
locyte lysates did not give rise to any proteins, as measured by either
[35S]methionine incorporation or Western blotting.
The ER has three primary functions that can be measured exper-
imentally (Green and Chambon, 1991): (1) ligand binding; (2)
specific DNA binding; and (3) transcriptional activation ofrespon-
sive genes. We measured these three functions using both the
wild-type ER and ER77 isolated from the MCF-7:2A cells. The
ligand-binding ability of these ERs was measured in two assays.
Firstly, we measured the ability of the ERs synthesized in vitro to
bind [3H]E2 in a HAP assay. As shown in Figure 3A, extracts
containing the wild-type ER specifically bound to this ligand with
a capacity equal to that of the HEGO-generated ER. In contrast,
the ER77 extracts did not measurably bind this ligand, showing no
more binding than the antisense extracts. These studies were
confirmed in an experiment that measured the ability of these
receptors to bind the anti-oestrogenic ligand [3H]tamoxifen aziri-
dine covalently (Wei et al, 1985; Fritsch et al, 1993). As seen in
Figure 3B, MCF-7:WS8 cytosol showed specific binding of a
protein that migrated at approximately 66 kDa. The MCF-7:2A
cytosol also contained a DNA-binding protein that migrated at
approximately 66 kDa, as would be expected from the wild-type
receptor identified in these cells. However, the MCF-7:2A cytosol
did not demonstrate any specific binding corresponding to the
ER77. These results could be predicted based upon previous data,
which have shown that point mutations in the steroid-binding
domain of the ER can cause alterations in ligand-binding ability
(Jiang et al, 1992b: Ince et al, 1993; Sluyser, 1995). We hypothe-
size that the duplication of exons 6 and 7, which causes the addi-
tion of over 100 amino acids to the ligand-binding domain of the
ER, would have dramatic effects on the ligand-binding function of
the ER77 protein. We show here that this effect is to abolish any
specific ligand binding in ER77.
The DNA binding of the ER from these cells was measured in
standard gel shift assays. In studies using nuclear extracts from
MCF-7:2A cells, the binding ofthe wild-type 66-kDa ER is easily
measured. However, even in lysates that have been depleted ofthe
wild-type ER by ICI 182 780 exposure, the ER77 does not appear to
bind the vitellogenin A2 ERE with a high affinity (Pink and Jordan
1996 and data not shown). We therefore used the receptor synthe-
sized in vitro to demonstrate DNA binding by the ER77 in isolation.
Wild-type ER bound this ERE well in the absence of ligand;
however, the addition of any ligand demonstrably increases DNA
binding regardless of whether the ligand is an oestrogen or anti-
oestrogen (see Figure 4). For the gel shift experiment observed in
Figure 5, we used unoccupied receptor to equalize the DNA
binding of the ER77 and the wild-type ER. We reasoned that the
lack of ligand-binding capability in the ER77 would serve to keep
this receptor in the 'unoccupied' state regardless ofthe presence of
ligand. The presence of ligand in the wild-type ER reactions
would, therefore, be expected to increase binding and overwhelm
the binding ofthe ER77. Lane 1 ofFigure 5 shows that the unoccu-
pied wild-type ER specifically binds this ERE, and lane 2 shows
that the antibody H222 can supershift this complex to completion.
Interestingly, the ER77 alone resulted in a complex, which
appeared as apoorly defined smear that ran with mobility similar to
the wild-type ER complex. The addition of the antibody, H222,
appears to have two important effects on the ER77 complex. Firstly,
the supershift demonstrates that this antibody can still recognize the
ER77/DNA complex. Secondly, H222 binding appears to stabilize
the DNA binding ofER77, as demonstrated by a significant increase
in signal intensity. The nature of the antibody stabilization of the
ER77 DNA binding is unclear. Furthermore, the cause ofthe diffuse
pattern ofthe ER77 binding was equivocal and may be the result of
any number of factors, such as modification of the ER77 protein
following translation in the reticulocyte extract or possibly some
form of oligomerization with other proteins present in the extract.
The duplicated segment present in ER77 may serve as a site for
specific modification not present in the wild-type ER. The expres-
sion of the ER77 protein in bacterial or baculovirus systems would
address this possibility. The interaction of the ER77 and the wild-
type ER was also assessed in experiments in which various ratios of
lysates containing the wild-type ER and/or the ER77 were mixed
and analysed in gel shift assays. In these experiments, there was no
indication of bands of intermediate mobility, which would be the
result ofheterodimerization ofthe two receptors, as has been shown
previously by Kumar and Chambon (1988) and data not shown.
The final ER function that was measured was the ability to
transactivate transcription-of a gene under the control of an ERE.
For this analysis, we employed two cell lines derived from the
well-studied human breast cancer cell line, T47D. T47D:A18 is a
subclone ofT47D, which is ER positive and oestrogen dependent.
T47D:C4:2W is a clone, which was derived following long-term
growth in oestrogen-free media and now grows maximally in
oestrogen-free media, and is ER negative (Pink et al, 1996b). The
use ofthese cell lines allowed us to measure the effect ofthe ER77
on both the endogenously and exogenously expressed ER. We do
not have an ER-negative clone derived from MCF-7 breast cancer
cells, so comparable experiments are not possible. As a target of
the transactivation, we chose a luciferase reporter system that was
under the control of three copies of the Xenopus vitellogenin A2
ERE. Data in Figure 6 showed that transfection of the wild-type
ER lead to oestrogen-dependent induction ofluciferase in the ER-
negative T47D:C4:2W cells. T47D:A18 cells exhibit this same
oestrogen-inducible response in the absence of transfected ER
owing to endogenously expressed ER. In this assay, ER77 does not
cause either constitutive or oestrogen-induced luciferase activa-
tion. In fact, ER77 inhibited the activity ofboth the exogenous and
endogenous ER (compare lanes 4 and 8 in Figure 6A-D). In co-
transfection groups, we chose a 1:5 ratio of ER77 to wild-type ER
in an attempt to mimic the ratio observed in MCF-7:2A cells.
These groups demonstrated that the ER77 can inhibit the trans-
activation capability ofthe wild-type ER.
An interesting result was obtained when oestrogen-free
T47D:A18 cells were transfected with wild-type ER alone. These
cells showed an approximately 15-fold increase in luciferase
activity. This response was also observed in transfections with the
MCF-7:WS8 cells (data not shown). However, when ER77 was
used, there was no increase in activity and the addition of ER77 to
the wild-type ER transfection caused an approximately 50%
decrease in the constitutive activity. The wild-type ER-mediated
E2-independent activity is not observed in T47D:C4:2W cells. This
suggests that in T47D:A18 cells, the constitutive expression of
exogenous ER can lead to the induction of transcription in
oestrogen-free media. This activity can be inhibited by co-transfec-
tion with ER77 in T47D:A18 cells. ER77 also inhibits endogenous
E2-stimulated activity in T47D:A18 cells, while co-transfection
with wild-type ER caused a 50% increase in luciferase activity.
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The induction of luciferase activity in T47D:C4:2W cells
observed in Figures 6C and D is quite different. Transfection ofthe
wild-type ER, mutant ER or a combination of these ERs showed
no induction of luciferase activity in the oestrogen-free groups. In
the E2-treated groups, transfection ofwild-type ER induced a >15-
fold induction in luciferase activity. In T47D:C4:2W cells, which
express no endogenous ER, the ER77 did not induce any luciferase
activity in response to E2. As observed in the T47D:A18 groups,
the addition of ER77 to the wild-type ER caused an inhibition of
luciferase activity below that seen with wild-type ER alone. These
results show that ER77 cannot function as a transcriptional acti-
vator of ERE-containing promoters and suggests that this mutant
ER is an inhibitor of normal ER function. Further investigation
will be necessary in order to elucidate fully the interaction of the
ER77 with the wild-type ER, as well as with other transcriptionally
active nuclear proteins.
Initially, we believed that the ER77 protein was responsible for
the oestrogen-independent growth and transcriptional activity
observed in the MCF-7:2A cells. The data presented here do not
support this position. In contrast, we found that increasing the
amount ofER in the T47D:A18 cells, through the use ofan exoge-
nous expression system, caused an increase in the oestrogen-
independent activation of the luciferase reporter gene. This
suggests that the mechanism forthe oestrogen-independent growth
in the MCF-7:2A cells may be the result of the increased expres-
sion of wild-type 66-kDa ER. Elevated expression of wild-type
ER may serve to activate genes, which are responsible for the
growth of the MCF-7:2A cell line in the absence of oestrogens.
This may be due simply to a mass action effect or, possibly, a non-
ligand-mediated activation pathway (Cho and Katzenellenbogen,
1993) that allows the ER to drive growth but not endogenous ER-
responsive genes, such as the PR. Alternatively, MCF-7:2A cells
may have adapted to growth in oestrogen-free media through the
activation of a pathway that caused activation ofthe ER77 through
a mechanism, which is not observed in transient transfection
studies. We propose that the ER77 may serve as a brake to prevent
that overstimulation of the growth pathways in these cells. This
is supported by the observation that oestrogen does not increase
the growth of the MCF-7:2A cells and, in fact, causes a slight
decrease in growth in a 6-day assay (Pink et al, 1995). It seems
likely that the MCF-7:2A cells have developed a delicate balance
of oestrogen-independent, ER-mediated activity that allows them
to proliferate in the absence ofexogenous oestrogens. Any pertur-
bation ofthis balance by either oestrogen oranti-oestrogens causes
a slowing of growth. Further investigations, including stable
expression of the ER77 protein in previously ER-negative cells,
will be necessary to elucidate the mechanism of action of this
mutant ER and its potential involvement in the development of
oestrogen-independent growth.
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